---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-400062"
form_type: "8-K"
ticker: "KYTX"
cik: "0001994702"
company_name: "Kyverna Therapeutics, Inc."
filed_at: "2026-09-24T10:00:27+00:00"
generated_at: "2026-09-24T10:05:38.425399+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Kyverna reports durable 1-yr SPS and gMG data; BLA on track Q4 2026

## Summary
- KYSA-8 SPS (n=26): median T25FW improvement 49% at 12 mo; 92% off chronic immunotherapies; no high-grade CRS/ICANS/IEC-HS.
- KYSA-6 gMG (n=7): 100% achieved clinically meaningful MG-ADL/QMG improvement at 24 wks; 57% maintained MSE; 86% off immunosuppressants.
- Rolling BLA for miv-cel in SPS on track for Q4 2026 completion; gMG Phase 3 enrollment expected mid-2027.
- Data to be presented at MS Toronto (Oct 21-23, 2026) and AANEM (Sept 29, 2026).
- Safety profile consistent: no high-grade CRS/ICANS and no IEC-HS across both trials through 1-yr follow-up.

## SEC filing metadata
- accession: 0001193125-26-400062
- form_type: 8-K
- ticker: KYTX
- cik: 0001994702
- company_name: Kyverna Therapeutics, Inc.
- filed_at: 2026-09-24T10:00:27+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1994702/000119312526400062/0001193125-26-400062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1994702/000119312526400062/kytx-20260924.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-400062
- JSON: https://secwatch.observer/filing/0001193125-26-400062.json
- Plain text: https://secwatch.observer/filing/0001193125-26-400062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.